Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 1
2021 3
2022 3
2023 2
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. Bestvina CM, et al. Among authors: jelinek mj. J Thorac Oncol. 2022 Jan;17(1):130-140. doi: 10.1016/j.jtho.2021.08.019. Epub 2021 Sep 6. J Thorac Oncol. 2022. PMID: 34500113 Free article. Clinical Trial.
Off the Top of Our Head.
Jelinek MJ, Joshi N. Jelinek MJ, et al. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):8-9. doi: 10.1016/j.ijrobp.2023.11.045. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631749 No abstract available.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
Rosenberg AJ, Juloori A, Jelinek MJ, Agrawal N, Cursio JF, Cipriani N, Lingen MW, Izumchenko E, Katipally R, Chin J, Ginat D, Pasternak-Wise O, Gooi Z, Blair E, Pearson AT, Haraf DJ, Vokes EE. Rosenberg AJ, et al. Among authors: jelinek mj. JAMA Oncol. 2025 May 1;11(5):492-501. doi: 10.1001/jamaoncol.2025.0081. JAMA Oncol. 2025. PMID: 40048190 Clinical Trial.
Adjuvant Osimertinib: A New Standard of Care.
Jelinek MJ, Aggarwal C. Jelinek MJ, et al. Oncologist. 2021 Apr;26(4):263-265. doi: 10.1002/onco.13634. Epub 2020 Dec 24. Oncologist. 2021. PMID: 33301209 Free PMC article.
Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies.
King K, Rauch R, Roy S, Menyok O, Tatebe K, Tajudeen B, Papagiannopoulos P, Batra PS, Bhayani M, Al-Khudari S, Stenson K, Jelinek MJ, Fidler MJ, Joshi N. King K, et al. Among authors: jelinek mj. Anticancer Res. 2022 Nov;42(11):5449-5455. doi: 10.21873/anticanres.16049. Anticancer Res. 2022. PMID: 36288895
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators. Fayette J, et al. Clin Cancer Res. 2025 Jul 1;31(13):2617-2627. doi: 10.1158/1078-0432.CCR-25-0073. Clin Cancer Res. 2025. PMID: 40300079 Free PMC article. Clinical Trial.
15 results